news, journals and articles from all over the world.
In a series of experiments with laboratory-cultured bacteria, Johns Hopkins scientists have found evidence that there is a second role for the widely used gene-cutting system CRISPR-Cas9 — as a genetic dimmer switch for CRISPR-Cas9 genes. Its role of dialing down or dimming CRISPR-Cas9 activity may help scientists develop new ways to genetically engineer cells for research purposes.
Researchers at the University of Pittsburgh School of Medicine have combined synthetic biology with a machine learning algorithm to create human liver organoids with blood and bile handling systems. When implanted into mice with failing livers, the lab-grown replacement livers extended life.
Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells’ ability to eliminate blood cancers.
Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.
A team of physicists and biologists investigate the effect that the geometry of the biological environment has on cellular movement. Their findings are published in the journal Science.
DALLAS – Nov. 12, 2020 – UT Southwestern researchers have discovered a mechanism that cells use to degrade microRNAs (miRNAs), genetic molecules that regulate the amounts of proteins in cells.
DALLAS – Oct. 29, 2020 – About half of all tumors have mutations of the gene p53, normally responsible for warding off cancer. Now, UT Southwestern scientists have discovered a new role for p53 in its fight against tumors: preventing retrotransposons, or “jumping genes,” from hopping around the human genome. In cells with missing or mutated p53, the team found, retrotransposons move and multiply more than usual. The finding could lead to new ways of detecting or treating cancers with p53 mutations.
FOR IMMEDIATE RELEASE CONTACT: Kathleen Haughney, University Communications (850) 644-1489; [email protected] @FSUResearch Florida State University professors as well as scientists around the world have benefited from the advent of CRISPR, the sophisticated genome editing technology that has revolutionized genetic research. The scientists Emmanuelle Charpentier and Jennifer A. Doudna received…
On behalf of the American Chemical Society (ACS), President Luis Echegoyen, Ph.D., congratulates today’s winners of the Nobel Prize in Chemistry: Emmanuelle Charpentier, Ph.D., and Jennifer A. Doudna, Ph.D. The Royal Swedish Academy of Sciences awarded the prize “for the development of a method for genome editing.”
Scientists are planning for Phase 1 human trials of a vaccine they developed by using CRISPR gene-editing technology to mutate the parasite that causes leishmaniasis, a skin disease common in tropical regions of the world and gaining ground in the United States.
UC San Diego researchers demonstrate that one dose of their version of CRISR gene editing can chew up toxic RNA and almost completely reverse symptoms in a mouse model of myotonic dystrophy, a type of adult-onset muscular dystrophy.
A potential therapy for obesity would transplant HUMBLE (human brown-like) fat cells, human white fat cells that have been genetically modified using CRISPR to become similar to heat-generating brown fat cells.
The August 2020 issue of Toxicological Sciences includes exciting advances in toxicology research. The edition features pieces on biotransformation, toxicokinetics, and pharmacokinetics; developmental and reproductive toxicology; and more.
Researchers at the Stowers Institute for Medical Research in Kansas City, Missouri, and the Andalusian Center of Developmental Biology at Pablo de Olavide University in Seville, Spain, have harnessed the technology to target gene messages (messenger RNA) involved in early vertebrate development.
In a series of experiments using human cancer cell lines, scientists at Johns Hopkins Medicine say they have successfully used light as a trigger to make precise cuts in genomic material rapidly, using a molecular scalpel known as CRISPR, and observe how specialized cell proteins repair the exact spot where the gene was cut.
A new analysis of difficult-to-access genetic variation is the most comprehensive ever conducted in plants. It could guide the improvement of tomatoes and other crops.
Scientists at Berkeley Lab and Stanford have joined forces to aim a gene-targeting, antiviral agent called PAC-MAN against COVID-19.
A new grant from the National Institutes of Health will allow Iowa State University scientists to continue to develop gene editing technologies to model human disease in zebrafish. The research aims to build new tools to determine which genes have therapeutic potential to treat human genetic diseases that affect the cardiovascular, immune and nervous systems.
During these difficult times, the Society of Toxicology’s official journal, Toxicological Sciences, remains a source for leading research in toxicology, including in the areas of biomarkers, carcinogenesis, and organ-specific toxicology.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia.
The March edition of SLAS Discovery features the cover article, “CRISPR: A Screener’s Guide,” by Carlos le Sage, Ph.D., Steffen Lawo, Ph.D., and Benedict C.S. Cross, Ph.D., (Horizon Discovery, United Kingdom). In their review, the authors discuss how CRISPR-Cas9 systems are being used widely throughout the drug discovery process and the development of new precision medicines.
In search of new ways to sequence human genomes and read critical alterations in DNA, researchers at Johns Hopkins Medicine say they have successfully used the gene cutting tool CRISPR to make cuts in DNA around lengthy tumor genes, which can be used to collect sequence information.
The February 2020 issue of Toxicological Sciences includes cutting-edge research spanning the toxicological field, from molecular, biochemical, and systems toxicology and nanotoxicology to regulatory science, risk assessment, and decision-making.
University of California San Diego School of Medicine researchers created a new type of brain cancer model for glioblastoma using stem cells, CRISPR and gene sequencing.
Promising intracellular protein-based therapeutics have been of limited use due to the difficulty of delivery into diseased cells. Now bioengineers have developed nanoparticles that can deliver these therapeutics to their targets—avoiding degradation and toxic interactions with healthy tissues.
Protein editorial assistants are clearing the way for cut-and-paste DNA editors, like CRISPR, to access previously inaccessible genes of interest. Opening up these areas of the genetic code is critical to improving CRISPR efficiency and moving toward futuristic, genetic-based assaults on disease. The DNA-binding editorial assistants were devised by a U.S.-based team of bioengineers, who describe their design in APL Bioengineering.
Below are summaries of recent Fred Hutch research findings with links for additional background and media contacts.
Researchers have developed a new CRISPR-based gene-drive system that more efficiently inactivates a gene rendering bacteria antibiotic-resistant. The new system leverages technology developed by UC San Diego biologists in insects and mammals that biases genetic inheritance of preferred traits called “active genetics.”
Researchers at the University of Delaware, using the revolutionary new genetic technology known as CRISPR/Cas9 have found a way to improve the efficiency and precision of the way enzymes work together to produce certain biochemical reactions in cells. Their new application essentially creates a dynamic assembly line that can lead to advances in pharmaceuticals, agriculture and biofuels.
Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States.
Researchers have designed a more precise and versatile genome editing system, named prime editing, that harnesses the power of CRISPR-Cas9 in combination with another protein, reverse transcriptase, to directly edit DNA in human cells.
What began as a 51-year-old mystery comes down to a single gene, as researchers from the University of Chicago and University of California, San Francisco discovered the cause of a new inherited form of pancreatitis.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu